Hylomorph solves the problem of fibrotic encapsulation encountered by all implantable medical devices. Hylomorph has developed a unique biomaterial which interacts with the sensing mechanism of cells thus maintaining the healthy interaction between device and tissue. Main markets include breast surgery implants and cardiac arrhythmia devices representing a total market opportunity of CHF 2.5bn worldwide.